Below is a mechanistic model that fits both the dependency pattern you observe and what’s known about ARIH2 biology.

Executive summary
- Genetic codependency points to a CRL5–neddylation addiction: ARIH2, UBE2F (NEDD8 E2 for CUL5), RNF7/RBX2, CUL5, DCUN1D5 (a DCN1-like neddylation co-E3), and SENP8 (NEDD8 protease) all rank among the top dependencies. This is the exact module required to neddylate and activate CUL5-based cullin–RING ligases (CRL5) and to execute their ubiquitination with ARIH2. ([reactome.org](https://reactome.org/content/detail/R-HSA-8952039?utm_source=openai))

Why ARIH2 loss is lethal in NCIH157DM
1) ARIH2 is the priming E3 for CRL5
- ARIH2 (Triad1) is an RBR E3 that binds neddylated CUL5–RBX2 and catalyzes the initial ubiquitin transfer to CRL5 substrates (with E2 UBE2L3); chain extension can then proceed via the CRL E2/RBX module. Structural and biochemical work shows ARIH2 is specifically activated by neddylated CUL5. Thus, removing ARIH2 cripples CRL5 substrate ubiquitylation even if the rest of the CRL5 machinery is intact. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24076655/?utm_source=openai))

2) The co-dependencies map exactly onto CRL5 activation
- UBE2F specifically neddylates CUL5 together with RBX2 (RNF7); DCUN1D5 promotes cullin neddylation; SENP8 is required to prevent aberrant neddylation of pathway components and to sustain optimal CUL5 neddylation. Dependence on all four argues that NCIH157DM survival hinges on a fully tuned CRL5 neddylation/deneddylation cycle feeding ARIH2. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27591266/?utm_source=openai))

3) Likely toxic substrates when CRL5–ARIH2 is disabled
- Pro‑apoptotic BH3‑only proteins: CRL5 promotes degradation of NOXA (PMAIP1) in lung cancer (via UBE2F–CUL5), and also regulates BIM and BIK in other contexts. If ARIH2 is removed, these pro‑apoptotic factors accumulate, pushing cells into mitochondrial apoptosis. This matches the strong co‑essentiality you see with UBE2F, RNF7 and CUL5. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27591266/?utm_source=openai))
- Nuclear cGAS: CRL5–SPSB3 targets nuclear cGAS for degradation. In a replication‑stressed cell (see SMARCAL1 dependency), impairing CRL5–ARIH2 could stabilize nuclear cGAS, triggering cytotoxic innate immune/replication stress responses. This is a plausible additional contributor to lethality upon ARIH2 loss. ([nature.com](https://www.nature.com/articles/s41586-024-07112-w?utm_source=openai))

4) Your dependency list strengthens the case
- PRDX1 is also a top hit. PRDX1 physically bridges UBE2F and CUL5 and enhances CUL5 neddylation, thereby accelerating NOXA degradation; blocking PRDX1 reduces CUL5 neddylation and raises NOXA. PRDX1 dependency therefore fits a CRL5–NOXA control axis. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33712558/?utm_source=openai))
- SENP8 dependence indicates the cell requires tightly regulated neddylation/deneddylation to keep CRL5 functional; SENP8 loss aberrantly neddylates NEDD8‑pathway enzymes, decreases UBE2F abundance, and compromises CUL5 neddylation. Such reliance suggests the line is “balanced on a knife‑edge” of CRL5 activity. ([elifesciences.org](https://elifesciences.org/articles/24325?utm_source=openai))

How mutations in NCIH157DM could set up this state
- KEAP1 missense variants are common in NRF2‑addicted NSCLC and associate with oxidative stress rewiring; in oxidized settings PRDX1 oligomerizes and strengthens the UBE2F–CUL5 neddylation of CRL5, tightening control over NOXA. Disrupting ARIH2 in this context would abruptly remove that brake on apoptosis. (Mechanistic link to PRDX1–CRL5 from colorectal cancer is direct; extrapolation to this lung line is a reasonable, testable inference.) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33712558/?utm_source=openai))
- Additional stressors (e.g., SMARCAL1 dependence, ATR variants, TP53 truncations) can heighten reliance on continuous clearance of pro‑apoptotic and stress‑response substrates by CRL5–ARIH2; loss of ARIH2 would then be particularly catastrophic. (Inference based on the CRL5 substrate literature above.)

Predictions you can test in this line
- Genetic rescues: Co‑KO or knockdown of PMAIP1/NOXA, BCL2L11/BIM, or BIK should partially rescue viability after ARIH2 KO; conversely, CUL5/UBE2F/RNF7 loss should phenocopy ARIH2 loss. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27591266/?utm_source=openai))
- Pharmacology: The neddylation inhibitor MLN4924 should mimic ARIH2 loss (and stabilize CRL5 substrates); a pan‑caspase inhibitor or enforced MCL1/BCL‑xL expression should blunt ARIH2‑KO lethality; if cGAS is involved, CGAS or STING knockdown should rescue. ([nature.com](https://www.nature.com/articles/s41586-024-07112-w?utm_source=openai))
- Biochemistry: After ARIH2 KO, expect increased NOXA/BIM/BIK protein, decreased CUL5 neddylation, and reduced ubiquitin‑priming on known CRL5 substrates; restoration with ARIH2 re‑expression should reverse these. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24076655/?utm_source=openai))

Bottom line
NCIH157DM appears “addicted” to a CRL5–neddylation circuit in which ARIH2 is the initiating E3 that primes ubiquitination on essential CRL5 substrates. Disabling ARIH2 collapses this circuit—stabilizing pro‑apoptotic factors (NOXA/BIM/BIK) and potentially nuclear cGAS—producing rapid cell death. The tight co‑dependency on UBE2F, RNF7, CUL5, DCUN1D5 and SENP8, plus PRDX1’s role in boosting CUL5 neddylation, all point to this same mechanism. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27591266/?utm_source=openai))

Selected references
- ARIH2–CRL5 coupling and activation by CUL5 neddylation: EMBO J 2013; Nat Struct Mol Biol 2021. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/24076655/?utm_source=openai))
- UBE2F/RBX2 specifically neddylate CUL5; DCUN1D5 promotes cullin neddylation. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27591266/?utm_source=openai))
- SENP8 maintains NEDD8-pathway homeostasis and supports CUL5 function. ([elifesciences.org](https://elifesciences.org/articles/24325?utm_source=openai))
- CRL5 substrates controlling apoptosis: NOXA (lung cancer), BIM and BIK. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/27591266/?utm_source=openai))
- PRDX1 links ROS to CRL5 by bridging UBE2F–CUL5 and enhancing CUL5 neddylation. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33712558/?utm_source=openai))
- CRL5–SPSB3 controls nuclear cGAS stability (potential second lethal substrate upon ARIH2 loss). ([nature.com](https://www.nature.com/articles/s41586-024-07112-w?utm_source=openai))

If you’d like, I can sketch a concise experimental workflow (genetic epistasis + pharmacology + substrate biochemistry) tailored to NCIH157DM to validate this mechanism.